Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Dow Jones Industrial Average ( ^DJI) is trading up 153 points (+1%) at 15,954 as of Tuesday, Feb 11, 2014, 12:35 p.m. ET. During this time, 164.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 379.5 million. The NYSE advances/declines ratio sits at 2,278 issues advancing vs. 692 declining with 140 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be Johnson & Johnson (NYSE: JNJ), which is sporting a $1.38 gain (+1.5%) bringing the stock to $92.44. This single gain is lifting the Dow Jones Industrial Average by 10.44 points or roughly accounting for 6.8% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at 5.2 million shares traded vs. an average daily trading volume of 8.1 million shares. Johnson & Johnson has a market cap of $254.04 billion and is part of the health care sector and drugs industry. Shares are down 1.7% year to date as of Monday's close. The stock's dividend yield sits at 2.9%. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.